# EDGAR Filing Document

**Accession Number:** 0001956827
**File Stem:** 0001956827-26-000014
**Filing Date:** 2026-4
**Character Count:** 5265
**Document Hash:** db39d3e33ff1caa5a98a3816e411bbb8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001956827-26-000014.hdr.sgml**: 20260420

**ACCESSION NUMBER**: 0001956827-26-000014

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260420

**FILED AS OF DATE**: 20260420

**DATE AS OF CHANGE**: 20260420

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Abivax S.A.
- **CENTRAL INDEX KEY:** 0001956827
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41842
- **FILM NUMBER:** 26875110

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7 BD HAUSSMANN
- **CITY:** PARIS
- **PROVINCE COUNTRY:** I0
- **BUSINESS PHONE:** 01 53 83 09 63

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7 BD HAUSSMANN
- **CITY:** PARIS
- **PROVINCE COUNTRY:** I0

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE** 

**SECURITIES EXCHANGE ACT OF 1934**

**For the month of April 2026**

Commission File Number: **001-41842**

**Abivax SA**

(Translation of registrant's name into English)

**7-11 boulevard Haussmann**

**75009 Paris, France**

**+33 (0) 1 53 83 08 41**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-

F. Form 20-F [ X ] Form 40-F [ ]

On April 20, 2026, Abivax SA (the "Registrant") published a press release entitled "Annual Ordinary and

Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents." A copy of the press

release is filed as Exhibit 99.1 to this Report on Form 6-K and is incorporated herein by reference.

The inclusion of any website address herein, including in any exhibit attached hereto, is intended to be an inactive

textual reference only and not an active hyperlink. The information contained in, or that can be accessed through,

such website is not part of this Form 6-K nor is it incorporated herein.

*Incorporation by Reference*

This Report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the

Registrant's registration statements on Form F-3 (File No. 333-283336 and 333-288884) and Form S-8 (File No.

333-286069 and 333-294544) and to be part thereof from the date on which this Report is filed, to the extent not

superseded by documents or reports subsequently filed.

---

| | |
|:---|:---|
| **<u>Exhibit Index</u>** |  |
| Exhibit 99.1 | [Press release, dated April 20, 2026](a260420_abivaxxprxagmprepa.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be

signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **<u>Abivax SA</u>** |
|  | (Registrant) |
| Date: April 20, 2026 | <u>/s/ Marc de Garidel</u> |
|  | Marc de Garidel |
|  | Chief Executive Officer |

---

## Exhibit 99.1

**Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026**

**Availability of the Preparatory Documents**

**PARIS, France, April 20, 2026, 10:05 PM CEST –** Abivax SA (Euronext Paris & Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, informs its shareholders that its ordinary and extraordinary general meeting (the "General Meeting") will be held on May 11, 2026, at 3:00 pm (CEST), at the hotel Paris Marriott Opera Ambassador, located at 16 boulevard Haussmann in Paris (75009), France.

The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the General Meeting, was published in the *Bulletin des Annonces Légales Obligatoires* (BALO) of April 3, 2026 (N°2600756).

The information and preparatory documents for this General Meeting are made available to the Company's shareholders in accordance with the procedures and within the time limits provided for by the applicable legal and regulatory provisions. The documents referred to in Article R.22-10-23 of the French Commercial Code are available on the Company's website: www.abivax.com

****

<br> **About Abivax** 

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

**Contact:**

Patrick Malloy<br>SVP, Investor Relations<br>Abivax SA<br>patrick.malloy@abivax.com<br>+1 847 987 4878

<br>